Digital Repository

Browsing by Author "Gunasekera, D."

Browsing by Author "Gunasekera, D."

Sort by: Order: Results:

  • Comparison of urban diabetics with optimal and suboptimal control 
    Pinidiyapathirage, M.; Warnakulasuriya, T.; Kasturiratne, A.; Ranawaka, U.; Gunasekera, D.; Wijekoon, N.; Medagoda, K.; Perera, S.; Takeuchi, F.; Kato, N.; Wickremasinghe, A.R. (British Medical Association, London, 2011)
    Introduction The prevalence of Diabetes Mellitus in Sri Lanka is increasing. We describe the characteristics of patients with optimal and suboptimal control of diabetes among known diabetics in a 35–64-year-old urban ...
  • Correlates of serum homocysteine in a Sri Lankan population 
    Chackrewarthy, S.; Wijayasinghe, Y.S.; Gunasekera, D.; Wickremasinghe, R.; Kato, N. (American Association For Clinical Chemistry, 2010)
    Correlates of total serum homocysteine concentration in a Sri Lankan population BACKGROUND: Hyperhomocysteinemia, a possible risk factor for vascular disease occurs at a higher prevalence in South Asian countries. Serum ...
  • Effect of mebendazole threapy in pregnancy on birth outcome 
    de Silva, N.; Sirisena, J.; Gunasekera, D.; de Silva, J. (Sri Lanka Medical Association, 1998)
    OBJECTIVES : A prospective, unmatched, case-control study was done to assess the safety of mebendazole threapy in pregnancy, a hitherto uninvestigated factor. DESIGN : All women delivering in the University Obstetrics Unit ...
  • Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination 
    López-Medina, E.; Biswal, S.; Saez-Llorens, X.; Borja-Tabora, C.; Bravo, L.; Sirivichayakul, C.; Vargas, L.M.; Alera, M.T.; Velásquez, H.; Reynales, H.; Rivera, L.; Watanaveeradej, V.; Rodriguez-Arenales, E.J.; Yu, D.; Espinoza, F.; Dietze, R.; Fernando, L.; Wickramasinghe, P.; Moreira Jr, E.D.; Fernando, A.D.; Gunasekera, D.; Luz, K.; da Cunha, R.V.; Tricou, V.; Rauscher, M.; Liu, M.; LeFevre, I.; Wallace, D.; Kosalaraksa, P.; Borkowski, A.; TIDES study group. (University of Chicago Press, 2022)
    BACKGROUND: Takeda's dengue vaccine is under evaluation in an ongoing Phase 3 efficacy study; we present an update after 2 years. METHODS: 20,099 children (4-16 years old) were randomized to receive two doses of TAK-003 ...
  • Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: A Randomised, placebo-controlled, phase 3 trial 
    Biswal, S.; Borja-Tabora, C.; Martinez Vargas, L.; Velásquez, H.; Theresa Alera, M.; Sierra, V.; Johana Rodriguez-Arenales, E.; Yu, D.; Wickramasinghe, V.P.; Duarte Moreira, E. Jr.; Fernando, A. D.; Gunasekera, D.; Kosalaraksa, P.; Espinoza, F.; López-Medina, E.; Bravo, L.; Tuboi, S.; Hutagalung, Y.; Garbes, P.; Escudero, I.; Rauscher, M.; Bizjajeva, S.; LeFevre, I.; Borkowski, A.; Saez-Llorens, X.; Wallace, D.; TIDES study group (J. Onwhyn, 2020)
    BACKGROUND: A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, ...
  • Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial 
    Tricou, V.; Yu, D.; Reynales, H.; Biswal, S.; Saez-Llorens, X.; Sirivichayakul, C.; Lopez, P.; Borja-Tabora, C.; Bravo, L.; Kosalaraksa, P.; Vargas, L.M.; Alera, M.T.; Rivera, L.; Watanaveeradej, V.; Dietze, R.; Fernando, L.; Wickramasinghe, V.P.; Moreira, E.D.; Fernando, A.D.; Gunasekera, D.; Luz, K.; Oliveira, A.L.; Tuboi, S.; Escudero, I.; Hutagalung, Y.; Lloyd, E.; Rauscher, M.; Zent, O.; Folschweiller, N.; LeFevre, I.; Espinoza, F.; Wallace, D. (Elsevier, 2024)
    BACKGROUND: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in preventing symptomatic dengue ...
  • Prevalence of metabolic syndrome in a Sri Lankan community 
    Chackrewarthy, S.; Gunasekera, D.; de Silva, L.D.R.; Pathmeswaran, A.; Wijekoon, C.N.; Ranawaka, U.K.; Mizoue, T.; Kato, N. (Sri Lanka Medical Association, 2008)
    OBJECTIVE: To estimate the prevalence of metabolic syndrome (MetS) in a Sri Lankan community. Limited information is available about MetS in Sri Lankans. DESIGN, SETTING AND METHODS: A total of 2948 individuals (1345 males ...
  • A secondary metabolite with in vitro radical scavenging activity from endolichenic fungus Daldinia eschscholzii found in lichen, Parmotrema sp. in Sri Lanka 
    Manthrirathna, M.; Kandiah, R.; Gunasekera, D.; Samanthi, K.; Welideniya, D.; Maduranga, H.; Paranagama, P. (Journal of the National Science Foundation of Sri Lanka, 2020)
    Endolichenic fungi, an unexplored group of microorganisms, are a promising source of bioactive compounds. Secondary metabolites were isolated from the chloroform fraction of crude ethyl acetate extract of endolichenic ...
  • Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003) 
    Rivera, L.; Biswal, S.; Sáez-Llorens, X.; Reynales, H.; López-Medina, E.; Borja-Tabora, C.; Bravo, L.; Sirivichayakul, C.; Kosalaraksa, P.; Vargas, L.M.; Yu, D.; Watanaveeradej, V.; Espinoza, F.; Dietze, R.; Fernando, L.; Wickramasinghe, P.; Duarte Moreira, E. J.; Fernando, A. D.; Gunasekera, D.; Luz, K.; Venâncio da Cunha, R.; Rauscher, M.; Zent, O.; Liu, M.; Hoffman, E.; LeFevre, I.; Tricou, V.; Wallace, D.; Alera, M.T.; Borkowski, A. (Oxford University Press, 2022)
    Background: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across eight dengue-endemic countries. Previously, we have reported its efficacy and ...

Search Digital Repository

Browse

My Account